Ameriprise Financial Inc Biocept Inc Transaction History

Ameriprise Financial Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.24 - $0.62 $161 - $417	-673 Reduced 5.48%	11,602 $3,000
Q4 2022 Feb 14, 2023	SELL	$0.47 - $0.89 $319 - $605	-680 Reduced 5.25%	12,275 $6,000
Q3 2022 Nov 14, 2022	SELL	$0.75 - $1.2 $145 - $232	-194 Reduced 1.48%	12,955 $12,000
Q2 2022 Aug 15, 2022	SELL	$0.88 - $2.27 $157,427 - $406,091	-178,895 Reduced 93.15%	13,149 $12,000
Q1 2022 May 16, 2022	BUY	$1.83 - $3.97 $6,578 - $14,272	3,595 Added 1.91%	192,044 $446,000
Q4 2021 Feb 14, 2022	BUY	$3.43 - $4.22 $596,175 - $733,486	173,812 Added 1187.48%	188,449 $682,000
Q3 2021 Nov 15, 2021	SELL	$3.39 - $4.34 $678 - $868	-200 Reduced 1.35%	14,637 $59,000
Q2 2021 Aug 16, 2021	SELL	$4.03 - $5.07 $1,785 - $2,246	-443 Reduced 2.9%	14,837 $62,000
Q1 2021 May 17, 2021	SELL	$4.74 - $7.94 $1,374 - $2,302	-290 Reduced 1.86%	15,280 $78,000
Q4 2020 Feb 12, 2021	SELL	$4.31 - $6.16 $1,012 - $1,447	-235 Reduced 1.49%	15,570 $69,000
Q3 2020 Nov 16, 2020	BUY	$3.61 - $11.4 $57,056 - $180,177	15,805 New	15,805 $70,000

Ticker BIOC
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,922,900
Market Cap $1.18M
Description
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for ...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.